Industry

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

Hepatic encephalopathy is a debilitating and recurring condition that causes neuropsychiatric conditions and is a common complication of cirrhosis.

Assessing the link between gut microbiome and neurodegenerative diseases to explore the potential of this critical field

Shahram Lavasani, Founder & CEO at ImmuneBiotech AB, spoke about how the research in gut-brain axes could pave the way to new microbiome based therapies in neurodegenerative diseases.

The Top Three Considerations for Successful Skin Microbiome Profiling

Bio-Me launching an extensive qPCR solution for skin microbiome analysis.

Sequential and Johnson & Johnson enter partnership to develop new genomic-based skin test

Oliver Worsley: ‘The collaboration will give us the opportunity to further understand how molecular changes on the skin may translate to skin and human health’.

Strategise how to best approach investors on the research of microbiome: a panel discussion

Tim Sharpington, Chief Executive Officer at Microbiotica, talked about how the microbiome field should navigate through a difficult financing horizon.

Stress management during the COVID-19 pandemic: new trial finds probiotics to benefit the quality of sleep and mood

New study shows that specific probiotics significantly contribute to the modulation of mood and sleep quality during stressful periods.

TargEDys: the potential of LpWJL as a potent probiotic supporting juvenile growth

New study shows that these probiotic properties are strain-specific and involve NOD2 signaling. Components of its cell wall could be novel postbiotics.

FMT in USA and EU: how the regulatory landscape is evolving 

Clara Desvignes, Head of Microbiome at VCLS, spoke about the continuously evolving regulatory landscape on Fecal Microbiome Transplant.

Sacco System launches Microbiome, the complete suite to support companies worldwide

Marco Caspani: ‘With the launch of our new Microbial Therapeutic business-line we are directing our efforts and strong focus to the field of Biotherapeutics’.

Holobiome and Johnson & Johnson enter partnership to develop next-generation probiotics for infant and maternal health

Microbiome platform company Holobiome announces collaboration to support infant and maternal immune health.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top